Pennsylvania Sued Insulin Makers and Benefit Managers
The state attorney general alleges a conspiracy to inflate insulin costs by over 1,000 percent for patients.
Updated on Oct. 13, 2026 in Diabetes
Live Poll
Should pharmaceutical companies and pharmacy benefit managers face legal action over rising insulin prices?
Pennsylvania Attorney General Dave Sunday has filed a lawsuit against major insulin manufacturers and pharmacy benefit managers. The complaint alleges that these companies conspired to manipulate price markets, which significantly increased out-of-pocket costs for residents across the state.
Why it matters
This litigation addresses systemic pricing practices that directly influence patient access to essential diabetes care. By targeting the alleged collusion between manufacturers and middlemen, the state aims to confront the financial barriers facing residents who rely on insulin for daily management.
The lawsuit, filed by the Pennsylvania Attorney General, presents claims of price market manipulation. It asserts that insulin prices were inflated by more than 1,000 percent through alleged collusion between manufacturers and pharmacy benefit managers.
The players
Dave Sunday
The Pennsylvania Attorney General who filed the lawsuit against insulin manufacturers and pharmacy benefit managers.
Eli Lilly and Co.
A pharmaceutical company that manufactures insulin products and is named as a defendant in the lawsuit.
Novo Nordisk
A global healthcare company focused on diabetes care that is named as a defendant in the lawsuit.
Sanofi-Aventis US
A manufacturer of diabetes medications named as a defendant in the legal complaint.
Express Scripts
A pharmacy benefit manager named in the lawsuit regarding its role in the insulin supply chain.
The details
The complaint alleges that manufacturers Eli Lilly and Co., Novo Nordisk, and Sanofi-Aventis US coordinated with pharmacy benefit managers Express Scripts, CVS Caremark, and Optum RX to artificially raise costs. These organizations reportedly acted in concert to inflate the price of insulin products at the expense of patients. The mechanism of the alleged manipulation centers on the relationship between manufacturer list prices and the processing systems managed by pharmacy benefit managers.
Timeline
October 13, 2026: Pennsylvania Attorney General announced the lawsuit.
Health Landscape
This lawsuit marks a continuation of state-level efforts to challenge the consolidated market influence of pharmacy benefit managers and insulin manufacturers. It reflects a growing tension between traditional drug pricing strategies and public policy aimed at lowering patient costs.
This legal development serves as a reminder to monitor your pharmacy costs and communicate with your healthcare provider if you struggle to afford prescribed treatments. Discuss available patient assistance programs or lower-cost alternatives with your doctor at your next visit.
The takeaway
The lawsuit highlights the financial impact of pharmaceutical market pricing on patient out-of-pocket expenses. Keep a record of your monthly insulin costs and reach out to your physician if rising prices create barriers to maintaining your treatment plan.
Further reading
For context on how to manage medication costs, explore our guide to Diabetes care resources.
Source note: This article includes information reported by Mlex.
Live Poll
Should pharmaceutical companies and pharmacy benefit managers face legal action over rising insulin prices?
